ReviewSarcoma2020
Diagnostic Value of TLE1 in Synovial Sarcoma: A Systematic Review and Meta-Analysis.
Review in Sarcoma, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 43 citations in OpenAlex.
- Diagnostic challenges in synovial sarcoma: a case report.Journal of medical case reports · 2026Article
- Systemic degradation of repressive transcription factors gates gene expression and cell fate specification.bioRxiv : the preprint server for biology · 2026Article
- Myoepithelial tumor withFrontiers in oncology · 2026Article
- Transducin-like enhancer of split-1 (TLE-1)-positive primary pleuropulmonary synovial sarcoma in a 14-year-old female adolescent: A case report and literature review.Radiology case reports · 2025Article
- Primary retroperitoneal synovial sarcoma (RSS): A case report.International journal of surgery case reports · 2025Article
- Case report: Primary cardiac synovial sarcoma with suspected connective tissue disease diagnosed by EBUS-TBMB.Frontiers in medicine · 2025Article
- The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma.Oncology research · 2025Review
- Unusual manifestation of synovial sarcoma: A rare case report with elevated beta HCG level.Radiology case reports · 2024Article
- Primary synovial sarcoma in anal canal: Report of a very rare case.Clinical case reports · 2024Article
- Rarest of the Rare - Malignant Solitary Fibrous Tumour of the Breast: Case Report and Literature Review.Maedica · 2024Article
- Synovial Sarcoma of the Hypopharynx in a Filipino Female: A Case Report.Acta medica Philippina · 2024Article
- Synovial sarcoma of the maxilla: A challenging diagnostic case report and literature review.Clinical case reports · 2023Article
- Microsecretory adenocarcinoma of the external ear canal.Journal of cutaneous pathology · 2023Article
- Article
- Clinicopathologic features of a patient with primary monophasic synovial sarcoma of the jejunum.Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences · 2022Article
- A potential diagnostic pitfall: Primary synovial sarcoma of the central nervous system.Free neuropathology · 2022Article
- Diagnosis of soft tissue tumors using immunohistochemistry as a surrogate for recurrent fusion oncoproteins.Seminars in diagnostic pathology · 2022Review
- miRNAs as Biomarkers and Possible Therapeutic Strategies in Synovial Sarcoma.Frontiers in pharmacology · 2022Review
- Roles of transducin-like enhancer of split (TLE) family proteins in tumorigenesis and immune regulation.Frontiers in cell and developmental biology · 2022Review
- The Biology of Synovial Sarcoma: State-of-the-Art and Future Perspectives.Current treatment options in oncology · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundSynovial sarcoma can present morphologically in multiple forms, including biphasic and monophasic subtypes. As a result, the histological diagnosis can sometimes be challenging. Transducin-Like Enhancer 1 (TLE1) is a transcriptional corepressor that normally is involved in embryogenesis and hematopoiesis but is also expressed in certain tumors. This systematic review examines the potential role of TLE1 as a diagnostic biomarker for the synovial sarcoma.
resultsThe mean sensitivity and specificity of TLE1 in detecting synovial sarcoma were 94% (95% CI 91%-97%) and 81% (95% CI 72%-91%), respectively, when all studies were aggregated together. The mean positive predictive value (PPV) of TLE1 was 75% (95% CI 62%-87%), whereas the negative predictive value (NPV) was 96% (95% CI 93%-98%).
conclusionTLE1 is a sensitive and specific marker for synovial sarcoma that can aid in its diagnosis. Due to its involvement in several relevant signaling pathways, TLE1 might have direct relevance to the pathophysiology of the disease.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.